Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

por Fabricio de Carvalho, Erico T Costa, Anamaria A Camargo, Juliana C Gregorio, Cibele Masotti, Valeria C C Andrade, Bryan E Strauss, Otavia L Caballero, Djordje Atanackovic, Gisele W B Colleoni
Publicado 2011